Kisspeptin — Research Reference

Kisspeptin is a family of neuropeptides encoded by the KISS1 gene, a gene originally characterised as a tumour suppressor. The KISS1 gene encodes a 145-amino-acid precursor protein (Kisspeptin-145) that is cleaved to yield a family of biologically active peptides sharing a common C-terminal decapeptide sequence: Kisspeptin-54 (the primary circulating form), Kisspeptin-14, Kisspeptin-13, and Kisspeptin-10 (the C-terminal decapeptide, most potent at the receptor level and most studied in research contexts).

All kisspeptin isoforms act via the KISS1R receptor (also called GPR54) — a G protein- coupled receptor expressed prominently in the hypothalamus and pituitary, where it plays a central role in regulating the hypothalamic-pituitary-gonadal (HPG) axis.

Quick Reference

Overview

Kisspeptin was identified as a regulator of reproductive function in 2003 when researchers discovered that loss-of-function mutations in KISS1R caused idiopathic hypogonadotropic hypogonadism (IHH) — a condition characterised by absent puberty and infertility. This finding established kisspeptin as a master regulator of the HPG axis.

Kisspeptin neurons in the hypothalamus — particularly in the arcuate nucleus and the anteroventral periventricular nucleus — integrate signals from sex steroids, metabolic state, and stress, then regulate the pulsatile release of gonadotropin-releasing hormone (GnRH). GnRH drives pituitary release of luteinising hormone (LH) and follicle-stimulating hormone (FSH), which in turn regulate gonadal steroidogenesis and gametogenesis.

Research has investigated kisspeptin for its potential role in:

• LH and GnRH secretion: Kisspeptin administration reliably stimulates LH secretion in humans — one of the most consistent pharmacological effects in the kisspeptin literature — and is proposed as a potential tool for investigating or modulating the HPG axis
• Male hypogonadotropic hypogonadism: Research has investigated kisspeptin administration as a potential approach to stimulating endogenous testosterone production in men with hypogonadism secondary to HPG axis dysregulation
• Ovulation induction: Clinical research has investigated kisspeptin for triggering ovulation in women undergoing IVF, with published data reporting successful oocyte maturation. This is one of the more clinically advanced kisspeptin research areas
• Sexual behaviour and attraction: Research has investigated kisspeptin for potential effects on sexual behaviour, with one study reporting that IV kisspeptin enhanced sexual brain processing in men
• Puberty and fertility disorders: Research has characterised the role of kisspeptin in puberty onset and its potential as a diagnostic and therapeutic target in disorders of puberty and fertility

Isoform Distinction

Understanding the different kisspeptin isoforms is important for interpreting research data.

Kisspeptin-10 (K-10): The C-terminal decapeptide (amino acids 45–54 of Kisspeptin-54). It is the most potent isoform at KISS1R and the most used in mechanistic and pharmacological research. Its shorter half-life (~28 minutes IV) makes it more suitable for pulsatile stimulation studies. Anecdotal research community use predominantly describes Kisspeptin-10.

Kisspeptin-54 (K-54): The primary circulating form. Longer half-life than Kisspeptin-10 due to its larger size. Clinical trials — including the IVF trigger studies and psychosexual research — have predominantly used Kisspeptin-54, as it more closely resembles the endogenous circulating peptide. Research accounts comparing K-10 and K-54 suggest broadly similar pharmacological effects on LH secretion, with differences in duration.

Reported Protocols

The following information represents published clinical research ranges and anecdotal research accounts. The clinical research base for kisspeptin is substantially more developed than for many other research peptides — it has been administered to hundreds of human participants in controlled trials. These are not medical recommendations.

Intravenous Protocol (Clinical Research)

Clinical trials have used IV kisspeptin to study HPG axis responses:

• Kisspeptin-54: Commonly used at 0.4–1.6 nmol/kg IV infusion; bolus or short infusion
• Kisspeptin-10: Used at 1–10 mcg/kg IV bolus in multiple published studies

Subcutaneous Protocol (Anecdotal Research)

In anecdotal research contexts, subcutaneous kisspeptin-10 doses are commonly described in the range of 50–200 mcg per injection, administered once or twice daily. Clinical bioavailability data for subcutaneous kisspeptin is limited.

Intranasal Protocol

Intranasal kisspeptin delivery has been investigated in research contexts. Doses are substantially higher than parenteral doses due to expected lower bioavailability via this route. Research nasal spray preparations have been described in the literature, though this route is less characterised than IV administration.

Reported Effects

LH and Testosterone Stimulation

Multiple controlled human studies have confirmed that kisspeptin administration reliably stimulates LH secretion — the most robust and reproducible finding in kisspeptin human research. In men, this LH pulse is followed by a rise in testosterone. The magnitude of LH response varies between individuals.

Ovulation Triggering

Published clinical trial data has reported successful use of kisspeptin-54 as an ovulation trigger in women undergoing controlled ovarian stimulation for IVF, with live birth rates comparable to conventional triggers in certain subgroups. This represents one of the most clinically concrete kisspeptin applications.

Effects on Sexual Processing

A randomised crossover study (Dhillo et al.) reported that IV kisspeptin-54 enhanced limbic brain responses to visual sexual stimuli and improved penile tumescence in healthy men — a psychosexual effect distinct from simple gonadotropin stimulation. Anecdotal research accounts describe subjective improvements in libido.

Puberty and Reproductive Axis Research

Kisspeptin research has substantially advanced understanding of HPG axis regulation, puberty onset, and neuroendocrine control of reproduction. This remains an active basic and clinical science research area.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following.

Kisspeptin has demonstrated a favourable tolerability profile in published clinical trials, with no serious adverse events prominently reported. The clinical research base, involving hundreds of participants across multiple institutions, provides greater safety context than is available for many research peptides. That said, the long-term effects of exogenous kisspeptin administration on HPG axis function have not been systematically studied.

Storage & Handling

Lyophilized Powder (Unreconstituted)

• Refrigerator (2–8°C): Preferred; protect from light
• Freezer: Acceptable for long-term storage; avoid repeated freeze-thaw cycles

Reconstituted Solution

• Refrigerator (2–8°C): Use within 4–6 weeks of reconstitution (BAC water)
• Do not freeze a reconstituted solution
• Discard if the solution becomes cloudy, discoloured, or shows particulate matter

Reconstitution

Add bacteriostatic water slowly along the inside wall of the vial. Swirl gently — do not shake. See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

Why is kisspeptin called a “tumour suppressor”? The KISS1 gene was originally discovered as a gene that suppressed melanoma metastasis — and its product was named metastin for this reason. The connection between KISS1 and reproductive regulation was not discovered until 2003. Research on kisspeptin’s potential role in cancer metastasis continues separately from its reproductive biology research.

Is kisspeptin suitable for low testosterone in men? Research has investigated kisspeptin for its ability to stimulate the HPG axis and raise LH and testosterone in men with hypogonadotropic hypogonadism — conditions where the HPG axis is intact but underactive. Kisspeptin would not be expected to stimulate testosterone in primary hypogonadism (where the testes themselves are the failing component). Anecdotal research accounts describe kisspeptin use in this context. No approved therapeutic exists.

What is the relationship between kisspeptin and GnRH analogues like triptorelin? Kisspeptin is upstream of GnRH — it stimulates GnRH neurons, which then release GnRH in pulses. GnRH analogues (triptorelin, buserelin, leuprolide) act at the GnRH receptor directly. Both stimulate LH secretion acutely; however, continuous GnRH agonist exposure desensitises the GnRH receptor and ultimately suppresses gonadotropin secretion (used in prostate cancer treatment). Pulsatile kisspeptin and pulsatile GnRH are proposed to maintain or restore HPG axis function rather than suppress it.

Is kisspeptin the same as Kisspeptin-10? Kisspeptin is a family of peptides; Kisspeptin-10 is the shortest, most potent isoform and is the one most commonly described in anecdotal research contexts. Kisspeptin-54 is the primary circulating form and the one most used in clinical trials. The terms are sometimes used interchangeably, which can cause confusion.

Related Pages

Goals: Testosterone & Hormonal Health · Fertility & Reproductive Health · Libido & Sexual Function

Class: Reproductive & Hormonal Peptides

References & Further Reading

• Dhillo WS, et al. (2005). Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in male humans. Journal of Clinical Endocrinology & Metabolism, 90(12), 6609–6615. PubMed →
• Jayasena CN, et al. (2014). Twice-weekly kisspeptin-54 administration in healthy men. Journal of Clinical Endocrinology & Metabolism, 99(5), 1682–1692. PubMed →
• Dhillo WS, et al. (2015). Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. Journal of Clinical Investigation, 125(9), 3651–3660. PubMed →